241
A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:December 7, 2018Unknown status
Refractory Multiple Myeloma: 1454 Clinical Trials, Page 25 of 146
Hide Studies Not Open or Pending
242
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:April 6, 2017Completed
243
Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:September 23, 2021No longer available
244
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:March 24, 2023Recruiting
245
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition(s):Multiple Myeloma (MM)Last Updated:April 22, 2022Recruiting
246
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:January 26, 2015Terminated
247
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:February 3, 2023Recruiting
248
A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
Condition(s):Multiple MyelomaLast Updated:November 23, 2021Recruiting
249
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:March 24, 2023Recruiting
250
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:July 18, 2022Active, not recruiting